Kymera Therapeutics, Inc. (KYMR)
79.67
-2.54
(-3.09%)
USD |
NASDAQ |
May 18, 16:00
79.77
+0.10
(+0.13%)
After-Hours: 20:00
Kymera Therapeutics Research and Development Expense (Quarterly) : 96.14M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.354B |
| Revolution Medicines, Inc. | 341.62M |
| Catalyst Pharmaceuticals, Inc. | 2.661M |
| Regeneron Pharmaceuticals, Inc. | 1.420B |
| AbbVie, Inc. | 2.472B |